The 20 Best Glioma Doctors Near Me in Rosedale, MD

Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG). Dr. Raabe is board certified in American Board Of Pediatrics.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine.

Henry Brem is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Brem is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Gliosarcoma, Glioma, Gliomatosis Cerebri, Osteotomy, and Posterior Fossa Decompression. Dr. Brem is board certified in American Board Of Neurological Surgery.

Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as an Elite provider by MediFind in the treatment of Glioma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Glioma, Brain Tumor, Astrocytoma, and Glioblastoma. Dr. Schreck is board certified in American Board Of Psychiatry And Neurology.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery. Dr. Kleinberg is board certified in American Board Of Radiology.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy. Dr. Weingart is board certified in American Board Of Neurological Surgery.

John Laterra is a Neurologist practicing medicine in Baltimore, Maryland. Dr. Laterra is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Alessandro Olivi is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Olivi is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Microvascular Decompression, and Craniectomy.

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Grossman is board certified in American Board Of Internal Medicine.

Dr. Debraj “Raj” Mukherjee’s clinical focus is the treatment of patients with primary and metastatic brain lesions. His clinical work and research emphasize the development of individual treatment plans that optimize survival and quality of life in all patients. After receiving his medical degree from Dartmouth Medical School, Dr. Mukherjee was recruited to Johns Hopkins, where he studied epidemiology, biostatistics and clinical design at the Johns Hopkins Bloomberg School of Public Health and served as Director of the Neuro-Oncology Surgical Outcomes Laboratory in the Department of Neurosurgery. Dr. Mukherjee completed neurosurgery residency at Cedars-Sinai Medical Center, where he was named a Robert Wood Johnson Foundation Health & Society Scholar. He completed an open and endoscopic skull base fellowship with the Center for Skull Base Surgery at University of Pittsburgh Medical Center, where he was a Copeland Scholar. Throughout his career, Dr. Mukherjee has led patient-centered research pursuits in neuro-oncology including development of a national registry for patients with brain tumors, creation of disease-specific quality of life instruments for patients with skull base tumors, and development of innovative clinical trials in neuro-oncology. He leads the Meningioma, Brain Metastasis, and Neurosurgical Oncology centers at Johns Hopkins Medicine, and he serves as Assistant Residency Program Director for one of the largest neurosurgical training programs in the country. His work has been supported by the American Medical Association, Glioblastoma Foundation, National Institute on Aging, and National Cancer Institute. Dr. Mukherjee can be contacted at drraj@jhmi.edu. Dr. Mukherjee is rated as a Distinguished provider by MediFind in the treatment of Glioma. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Meningioma, Pituitary Tumor, Brain Tumor, Awake Craniotomy, and Craniectomy. Dr. Mukherjee is board certified in American Board Of Neurological Surgery.

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as an Elite provider by MediFind in the treatment of Glioma. He is also highly rated in 38 other conditions, according to our data. His clinical expertise encompasses Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression. Dr. Bettegowda is board certified in American Board Of Neurological Surgery.

Jordina Rincon-Torroella is a fellowship-trained neurosurgeon specializing in the surgical treatment of benign and malignant tumors of the brain and skull base, such as meningiomas, gliomas, pituitary tumors and metastatic brain tumors, to name a few. Dr. Rincon-Torroella earned her medical degree from the University of Barcelona medical school. She completed a postdoctoral fellowship in neurosurgical oncology at Johns Hopkins University, where she remained for residency training in neurosurgery. She completed an additional postdoctoral fellowship in cancer research and drug development at Johns Hopkins in the Ludwig Center under the mentorship of neurosurgeon Chetan Bettegowda and molecular biologist and geneticist Bert Vogelstein. Active in clinical research since 2010, Dr. Rincon-Torroella has published numerous research papers. She is also a peer reviewer for several journals and has edited two books, most recently The Neurosurgical Consult Book. Dr. Rincon-Torroella is fluent in Catalan, English and Spanish. Dr. Torroella is rated as an Advanced provider by MediFind in the treatment of Glioma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Subependymoma, Ependymoma, Brain Tumor, Laminectomy, and Craniectomy.

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as an Advanced provider by MediFind in the treatment of Glioma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy. Dr. Pratilas is board certified in American Board Of Pediatrics.

Tej Azad is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Glioma. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Spinal Tumor, Traumatic Brain Injury, Subdural Hematoma, Spinal Fusion, and Laminectomy.

Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine. Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. Dr. Seiwert served as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He was a member of the NCI Head and Neck Cancer Steering Committee, and is a member of the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, and the European Society of Clinical Oncology. Dr. Seiwert is rated as a Distinguished provider by MediFind in the treatment of Glioma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy. Dr. Seiwert is board certified in American Board Of Internal Medicine.

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Glioma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Glioma, Medulloblastoma, Brain Stem Cancer, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration. Dr. Cohen is board certified in American Board Of Pediatrics.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as a Distinguished provider by MediFind in the treatment of Glioma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Glioma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor. Dr. Redmond is board certified in American Board Of Radiology.

David Kamson is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Glioma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Metastatic Brain Tumor, Gliosarcoma, and Hormone Replacement Therapy (HRT). Dr. Kamson is board certified in American Board Of Psychiatry And Neurology.

Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as an Experienced provider by MediFind in the treatment of Glioma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy. Dr. Hales is board certified in American Board Of Radiology.